Introduction
Investment in strengthening laboratory systems in resource-poor countries is critical to meet health needs across major diseases such as HIV/AIDS and to meet the United Nations Millennium Development Goals. 1 In the past decade, the US government has invested over $15 billion in HIV prevention, care and treatment in low-and middle-income countries via the President's Emergency Plan for AIDS Relief (PEPFAR). 2 This support has included a wide range of activities aimed at strengthening health services, including laboratories, to provide services for persons living with HIV (PLWH). Although the positive impact of these targeted health services on PLWH is undeniable, the effect of HIV service scale-up on broader health systems, including services for patients without HIV, has been debated. 3, 4, 5, 6, 7 Since 2006, PEPFAR has provided over $440 million to strengthen laboratory systems through improved infrastructure and equipment, human resources and training, quality improvement, and technical assistance. 8 This investment has expanded laboratory services such as diagnostic and monitoring tests for PLWH. Because these laboratory investments support health facilities serving a broad population of patients, not just PLWH, it is plausible that they may have affected, or in the future could affect, the coverage and quality of laboratory services used by the general population -that is, individuals with no known HIV infection. 9 To our knowledge, no studies have explored this question yet.
In an effort to describe PEPFAR's investment in laboratory services for the general population, we analysed routinely collected programmatic data from selected public laboratories in Tanzania. Specifically, we selected a convenience sample of PEPFAR-supported laboratories in Tanzania, which are supported through ICAP at Columbia University. 10 In these laboratories, the only information distinguishing the HIV status of the patient from whom the test was collected was the test's referral source; that is, an HIV service or a non-HIV service (NHS) (e.g. general medical or outpatient services). Although referral source is not a definitive diagnosis of HIV status, it was the only routinely recorded information available as a proxy for HIV status. Our primary objective was to describe the number and proportion of selected core laboratory tests performed for patients referred from the respective services in 2011. A secondary objective was to compare changes in proportions of tests performed for patients referred from NHSs in 2009 and 2011. 
Research method and design

Ethical considerations
Study population
We conducted a retrospective cross-sectional analysis of laboratory tests from 2009 and 2011 in a convenience sample of PEPFAR-supported public laboratories in Tanzania. All laboratories received PEPFAR support from ICAP at Columbia University. Laboratories that were included were all categorised as public sector, offered integrated laboratory services for all laboratory samples (i.e. using the same staff and equipment for HIV and non-HIV patients), performed at least haematology testing over the study period, and had available laboratory register data on preliminary assessment. Data abstracted from laboratory testing registers did not include patient-identifying information. 
Definitions of laboratory tests and outcomes
Site-level variables
Programmatic information was used to provide contextual information about included laboratories. Routinely collected quarterly monitoring and evaluation data from the co-located HIV care and treatment facilities were used to quantify the number of years each facility had provided HIV care services and the number of HIV-positive patients enrolled in the HIV care service. Information from facility-based surveys completed in 2009 and 2011 at laboratories included the location type (urban vs rural) and type of facility (primary, secondary or tertiary); the 2011 survey also described the number of trained laboratory personnel working in each laboratory.
Data collection
Between March and July of 2013, study staff extracted deidentified laboratory data from on-site hard-copy registers at included laboratories. Study staff met briefly with laboratory personnel to assess the availability of laboratory registers for each of the aforementioned tests. Study staff reviewed the available laboratory registers to tally the number of each type of test conducted per month. Totals were aggregated by the type of referral source. If an HIV clinic was indicated as a referral source, the test was categorised as coming from an HIV service. If another clinic or unit within the facility was documented as the source in the register, the test was categorised as coming from a NHS. If no source was documented for the patient, the test was categorised as coming from an unknown referral source.
Statistical analysis
Proportions of tests conducted amongst all the laboratories were calculated for specimens referred from HIV services, NHSs and those with an unknown referral source. Proportions were calculated by year and by test type. A generalised linear mixed model was constructed to predict the odds that a laboratory test was referred from a NHS, taking into account intrafacility correlations. We used a generalised linear mixed model without confounders to account for intrafacility correlation, and an adjusted generalised linear mixed model that controlled for key facility-level variables including year, facility location and total volume of tests performed at each facility as fixed effects, with the laboratory treated as the random effect. Key contextual variables hypothesised to affect the proportion of tests from an HIV service compared with from a NHS, such as location (rural vs. urban), region, facility type and service size (e.g. number of patients enrolled in HIV care) were assessed individually to determine an unadjusted odds ratio. Candidate confounders (P < 0.25 when unadjusted) were entered and examined in generalised linear mixed models, but only the significant variables (P < 0.05) were kept in the final models for the purposes of calculating the adjusted odds ratios. All analyses were conducted using SAS version 9.3 (SAS Institute, Cary, North Carolina, United States).
Results
Amongst the 127 PEPFAR-supported laboratories in Tanzania 
Characteristics of laboratory facilities
The majority of laboratories were located in an urban area ( 
Characteristics of laboratory tests
The total number of tests recorded increased from 94 132 in 94 laboratories in 2009 to 157 343 in 101 laboratories in 2011 ( Table 2 ). The proportion of all tests performed for patients referred from a NHS increased from 31% ( 
ProporƟon of laboratory tests (%)
Hematology Chemistry Tuberculosis Syphilis All Tests
Unknown referral source Non-HIV service HIV service Samples that came from laboratories that conducted fewer tests (≤ 500 and 501-1500 per year) were more than twice as likely to be referred from NHSs compared with those from laboratories that conducted a larger number of tests (> 1500) per year (adjusted odds ratios: 2.5 [95% CI: 1.9-3.3] for ≤ 500 tests and 2.6 [95% CI: 2.3-2.9] for 501-1500 tests).
Discussion
We investigated the potential impact of PEPFAR-supported laboratory scale-up on the general (non-HIV) patient population in a country in sub-Saharan Africa. The results describe the number of laboratory tests performed in 2009 We were unable to examine the effect of facility type (primary, secondary, tertiary) or region owing to small sample sizes in the variable categories. As a result, they were not included in the final models. Empty cells indicate that the regression model did not converge and no estimate was calculated; ¶, Unadjusted odds ratios account for intrafacility correlation; §, Adjusted for intrafacility correlation and facility-level characteristics including year, location and total number of tests performed at each facility.
and 2011 in a convenience sample of PEPFAR-supported laboratories in Tanzania and the proportion of tests performed for patients referred from HIV services, NHSs and unknown sources. A key finding in this analysis is the substantial increase in the proportion of all tests referred from NHSs from 2009 to 2011 -both when including all laboratory tests and when including only tests with known referral sources.
There was considerable variation in the number of tests performed by each facility (IQR: 108-1211 tests in 2009 and 217-2034 in 2011). Also of note was the substantial variation in testing volume across different types of laboratory tests. Haematologic tests were the most common type and are the laboratory cornerstone for antenatal care, malaria diagnosis and treatment, routine outpatient diagnostics for infectious diseases, and HIV care. Syphilis tests were the least common test; however, the volume of syphilis tests increased substantially from 2009 to 2011, reflecting in part a Tanzania Ministry of Health recommendation for rapid tests kits (SD Bioline), which enabled routine point-of-care syphilis screening to become more feasible, as opposed to rapid plasma reagin, which require cold-chain analysis and trained laboratory staff.
Chemistry tests were performed most often for patients referred from HIV services, which may reflect the clinical practice of assessing renal function amongst HIV patients before and during antiretroviral therapy. 11 It is difficult to interpret changes in tuberculosis testing given that the majority of laboratory registers did not record a referral source in this category.
Referral sources were not reported for any tests by 46% (43/94) of laboratories in 2009 and 40% (40/101) of laboratories in 2011. It was not possible to infer the HIV status of these patients. In laboratories with unknown referrals amongst some tests, the intermittent lack of referral documentation may be due to random missing data at the laboratory. Alternatively, in some laboratories, technicians may prioritise documentation of samples from HIV clinics and leave all other referral sources blank, leading to samples referred from NHSs and those without a referral source being grouped together. In this scenario, patients with unknown referral sources would be more likely to represent the general population. If unknown referral sources were actually non-HIV patients, our data suggest little meaningful change in the proportion of tests referred from NHSs between 2009 and 2011, relative to tests referred by HIV services.
Limiting the analysis to laboratories that did record a referral source restricted the sample size to 51 in 2009 and 61 laboratories in 2011. Within this subgroup, the proportion of tests referred from NHSs increased across all test types, similar to analyses including the full sample of laboratories. A model was used to predict the odds that an individual test was referred from a NHS, given that individual tests are not independent of each other in a laboratory. Using this model, the probability of a test being referred from a NHS was two times higher in 2011 than in 2009. Notably, haematology and tuberculosis tests were less likely to be referred from a NHS in 2011 than in 2009. This finding may be due to the model taking into account the correlation of the laboratory tests within a specific site when estimating the odds ratios. For example, larger laboratories may have skewed the results reported in Figures 2 and 3 , but once intrafacility correlation is accounted for, the proportion of tests referred from NHSs for haematology and tuberculosis appeared to decrease over time. These findings suggest a large amount of site-level variation in the odds of a test being referred from NHSs. In addition, the observed odds ratio for all tests was likely driven by the increases in NHS testing in chemistry and syphilis between 2009 and 2011.
Limitations
This study has several limitations. Firstly, the data comprised a non-random convenience sample of laboratories. Thus, the results may not be generalisable to other PEPFAR-supported laboratories in Tanzania or in other PEPFAR-supported countries. It is also unknown, in the absence of a comparison group, whether the volume of laboratory tests referred from HIV services and NHSs would have changed in the absence of PEPFAR or at comparable public laboratories not supported by PEPFAR. Secondly, it would have been advantageous to describe the change in laboratory tests over a longer period. However, this was not feasible, as ICAP support for most study laboratories began in 2009. Thirdly, because the sources of the laboratory data did not record identifiable patient information, the unit of analysis in this study was a laboratory test and not an individual patient, who could have had multiple tests. As stated previously, the HIV status of the patient for whom each test was performed was unknown. Future analyses evaluating utilisation of laboratory services at the patient level would provide additional information as to whether there are differences in laboratory usage according to patients' HIV status. Fourthly, our data did not include information on the reason for a test being ordered for samples referred from NHSs. Thus, we could draw no conclusions as to whether or how guidelines for laboratory testing amongst non-HIV patients influenced utilisation of laboratory services. Finally, we were limited by the availability of hard-copy laboratory registers. The absence of a register did not necessarily mean that tests were not performed in a given laboratory, but merely that we were unable to access documentation of the test being performed. Even when registers were available, only 54% (51/94) of laboratories in 2009 and 61% (61/101) of laboratories in 2011 recorded referral sources; amongst those that did, we could not verify the referral source against other records. However, data availability and quality are unlikely to have changed notably over the study period.
This study provides descriptive data as a departure point for answering the question of how PEPFAR's investment in laboratory services may have influenced utilisation of laboratory services by the general population. A systematic impact evaluation would be beneficial and would require prospective data or comparison groups and should include data on other variables about serviced populations, including the HIV status of patients for whom laboratory tests are performed, and laboratory characteristics, including staffing, equipment, training, quality improvement and costs.
Conclusion
This retrospective study found that in a convenience sample of PEPFAR-supported laboratories in Tanzania, the number and proportion of tests performed for patients referred from NHSs increased for all tests from 2009 to 2011 compared with referrals from HIV services. The increase was driven in part by chemistry and syphilis testing. Although these findings are descriptive and may not be generalisable to other HIVsupported laboratories in Tanzania and other resource-limited countries, this finding may reflect increased documentation of referrals from NHSs in laboratory registers over time. Another possibility is that laboratory scale-up originally intended to service the HIV-positive population in Tanzania may be associated with a 'spillover effect' on laboratory use amongst the general population in the sampled facilities. These data may inform subsequent prospective studies to evaluate the impact of PEPFAR-supported laboratory scaleup on utilisation of laboratory services and the impact on health outcomes amongst the general population
